Business
enGene to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
BOSTON & MONTREAL--(BUSINESS WIRE)-- enGene Holdings Inc. (Nasdaq: ENGN or “enGene” or the “Company”), a clinical-stage genetic medicines company whose
About this update from Engene Therapeutics Inc.
[{"type":"text","content":" BOSTON & MONTREAL--(BUSINESS WIRE)--\nenGene Holdings Inc. (Nasdaq: ENGN or “enGene” or the “Company”), a clinical-stage genetic medicines company whose non-viral lead investigational product detalimogene voraplasmid (also known as detalimogene, and previously EG-70) is in an ongoing pivotal study in patients with high-risk, Bacillus Calmette-Guérin (BCG)-unresponsive, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS), today announced that Alex Nichols, Ph.D., Chief Strategy and Operations Officer, will present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference, taking place virtually on Tuesday, February 11, 2025 at 8:40 a.m. ET.\n\n\nA live webcast of the presentation can be accessed under the “Investors” section of the enGene website at www.engene.com and will be archived there for 90 days.\n\n\nAbout enGene\n\n\nenGene is a clinical-stage biotechnology company mainstreaming genetic medicines through the delivery of therapeutics to mucosal tissues and other organs, with the goal of creating new ways to address diseases with high clinical needs. enGene’s lead program is detalimogene voraplasmid, (also known as detalimogene, and previously EG-70) for patients with Non-Muscle Invasive Bladder Cancer (NMIBC) – a disease with a high clinical burden. Detalimogene is being evaluated in the ongoing multi-cohort LEGEND Phase 2 study, which includes a pivotal cohort studying detalimogene in Bacillus Calmette-Guérin (BCG)-unresponsive patients with carcinoma in situ (CIS). Detalimogene was developed using enGene’s proprietary Dually Derivatized Oligochitosan (DDX) platform, which enables penetration of mucosal tissues and delivery of a wide range of sizes and types of cargo, including DNA and various forms of RNA. For more information, visit enGene.com.\n\nView source version on businesswire.com: https://www.businesswire.com/news/home/20250204642828/en/\n\nFor media contact:\n908-577-4531\[email protected]\n\n\nFor investor contact:\[email protected]\n\n\nSource: enGene Holdings Inc.","length":3458,"tagName":"div"}]